Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Labcorp and Roche collaborate to expand access to advanced precision testing

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

January 30, 2026

Vol.52 No.04

Drugs & Targets

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

HanchorBio, a global clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization, jointly announced the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.

January 23, 2026

Vol.52 No.03

In Brief

SU2C + CRUK secure $3M for gastric cancer research

Stand Up To Cancer and Cancer Research UK secured $3 million in new support for a “dream team” focused on stopping gastric cancer in its earliest stages.

January 16, 2026

Vol.52 No.02

Cancer Policy

Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe

Regulatory Toxicology and Pharmacology has retracted a literature review published in 2000 that concluded that glyphosate, a common herbicide used in agriculture and found in products such as Roundup, “does not pose a health risk to humans.”

American Center for Cures and BlueCloudX collaborate to accelerate cures, modernize healthcare and clinical research

American Center for Cures and BlueCloudX announced a strategic collaboration aimed at accelerating the development of cures for major diseases while dramatically reducing the time, cost, and complexity of clinical research.

January 09, 2026

Vol.52 No.1

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

YOU MAY BE INTERESTED IN

Labcorp and Roche collaborate to expand access to advanced precision testing

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

SU2C + CRUK secure $3M for gastric cancer research

Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe

American Center for Cures and BlueCloudX collaborate to accelerate cures, modernize healthcare and clinical research

Renew today!

Subscriber content

Never miss an issue!

Login